Moving away from pharma’s paternalistic approach
September 12, 2018 | Patient-centric, Patient-centricity, life sciences, patient engagement
New handbook makes the case for greater patient engagement in the development of new medicines
12 September 2018, Cambridge, UK—The pharmaceutical industry has achieved great success in delivering innovative medicines, but life science companies must become ever more consumer-centric if they are to realise the step change in improving patient outcomes that their science promises, according to a new patient engagement handbook released today. 
Patient Engagement for the Life Sciences by Guy Yeoman and Mitchell Silva explains the ‘why’ and the ‘how’ of patient engagement, presenting the compelling argument for why life science companies need to embrace and partner with patients and outlining an operating framework for doing it effectively.
“It’s so important to shift from patient-centric rhetoric to an integrated model where life cycle decisions are informed by patient insight and patient solutions are created with patients,” Yeoman commented.
Guy Yeoman has worked for the last two decades in the pharmaceutical industry, and in the last three years he built a patient-engaging capability in a large pharma organisation. Mitchell Silva is a patient expert and Chair of the European Patients’ Academy (EUPATI) in Belgium. They are co-founders of MediPaCe, a strategic consultancy that works with the life science industry to make patient engagement a reality. 
In Patient Engagement for the Life Sciences, the authors discuss the future of the pharmaceutical industry and how a number of drivers — including digital technology, patient expectations, outcomes-based payments and spiralling R&D costs — will make co-creating medicines with patients crucial to pharma companies’ ability to continue to deliver patient value.
It goes on to describe the framework necessary for embedding patient engagement into business practice, and the process for transforming into a company with patients at the centre of its culture.
Silva said, “Patients increasingly want to contribute to the development of better medicines and better services to support new treatments, but often the infrastructure to involve patients in a structural way is lacking. Patients are waiting to contribute.”
Cuttsy+Cuttsy provided editorial support, cover design and illustrations for the publication. Director Caroline Benson said, “As a healthcare communications agency where people matter, Guy and Mitchell’s book aligned perfectly with our company values. We were delighted to help bring it to life, as working with patients to make sure products and services work for them is what we have always done, and we truly believe that it gives the best results for everyone.”
Patient Engagement for the Life Sciences is now available as an eBook. Any profits generated from book sales will be donated to International Health Partners UK, Europe’s largest coordinator of donated medicines, to support patients around the world.
Download your copy from www.medipace.com/book
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
From cloudy to clear: visualising complex data privacy information
Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.
UK clinical trial regs are changing — here’s what’s happening
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
The invisible influence on trial retention: why caregivers must be part of the plan
Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and how to better support them.
Where it all began: why we wrote ‘The Site Factor’
Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.
From text to context: Helping patients see side effects clearly
Discover how thoughtful design, clear language, and structured visuals can transform overwhelming side effect information into accessible, actionable insights for patients in our latest Health Literacy series.
Why patient engagement must come first in rare disease trials
Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.
New Cuttsy+Cuttsy research shows why site support matters more than ever
Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...
Cuttsy+Cuttsy becomes employee owned
Cuttsy+Cuttsy announces its transition to employee ownership, celebrating 15 years of prioritising clients, patients, and its team while continuing under the leadership of founders Caroline Benson and Mathew Cutts.
Clinical research in 2026: The trends shaping tomorrow
Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.
From overwhelming to actionable: Bringing lifestyle guidance to life
Discover how clear communication and health literacy principles can transform complex patient materials into simple, engaging, and empowering health information.